Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2015.

Targeted cancer drugs are all the rage--and with good reason--but it remains challenging to accurately predict which patients will respond to them. BioMarker Strategies LLC has developed SnapPath, an ex vivo biomarker system that disperses solid tumor tissue in media. It then exposes live cells to growth factors and other stimuli to induce them to produce phosphoproteins and other ex vivo biomarkers to reveal the functional circuitry of the patient's tumor cells.